- Treffer 1 von 1
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-144537
- Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the firstChemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.…
Autor(en): | Hans Jürgen Wester, Ulrich Keller, Margret Schottelius, Ambros Beer, Kathrin Philipp-Abbrederis, Frauke Hoffmann, Jakub Šimeček, Carlos Gerngross, Michael Lassmann, Ken Herrmann, Natalia Pellegata, Martina Rudelius, Horst Kessler, Markus Schwaiger |
---|---|
URN: | urn:nbn:de:bvb:20-opus-144537 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Medizinische Fakultät / Pathologisches Institut | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Theranostics |
Erscheinungsjahr: | 2015 |
Band / Jahrgang: | 5 |
Heft / Ausgabe: | 6 |
Seitenangabe: | 618-630 |
Originalveröffentlichung / Quelle: | Theranostics 2015; 5(6): 618-630. DOI: 10.7150/thno.11251 |
DOI: | https://doi.org/10.7150/thno.11251 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | CXCR4; acute myeloid leukemia; chemokine receptor; in vivo imaging; lymphoma; positron emission tomography; prognostic value; therapeutic target |
Datum der Freischaltung: | 21.06.2018 |
Lizenz (Deutsch): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International |